Vertex Pharmaceuticals (VRTX) Price Target Upgraded at Summer Street Research

Vertex Pharmaceuticals (VRTX) received a “buy” rating reiteration today from investment firm Summer Street Research.  Summer Street also increased their price target for VTRX a substantial amount from $46 to $72 dollars.  VTRX is currently trading above its 50 & 200-day moving averages and 2011 is currently an up year for the company.

Vertex Pharmaceuticals in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. In November 2010, they submitted a new drug application, or NDA, requesting approval to market telaprevir in the United States for the treatment of patients with chronic hepatitis C virus, or HCV, infection.  The company has market capitalization of $11,036,000,000 and 204,413,000 shares outstanding.  VTRX has a 52-week high of $58.87 with the low being $31.25 dollars.

Latest News

Elementrem  Reaches 24-Hour Trading Volume of $28.00
Elementrem Reaches 24-Hour Trading Volume of $28.00
Oceanlab  Price Reaches $0.0092 on Top Exchanges
Oceanlab Price Reaches $0.0092 on Top Exchanges
Hannon Armstrong Sustnbl Infrstr Cap Inc  Expected to Announce Quarterly Sales of $13.81 Million
Hannon Armstrong Sustnbl Infrstr Cap Inc Expected to Announce Quarterly Sales of $13.81 Million
Host Hotels and Resorts Inc  Expected to Post Quarterly Sales of $1.28 Billion
Host Hotels and Resorts Inc Expected to Post Quarterly Sales of $1.28 Billion
NEVERDIE  Hits Market Cap of $439,225.00
NEVERDIE Hits Market Cap of $439,225.00
Scorecoin  Trading 2.8% Lower  Over Last Week
Scorecoin Trading 2.8% Lower Over Last Week


© 2006-2018 Ticker Report. Google+.